DUBLIN, July 08, 2015 /PRNewswire/ --
Research and Markets(http://www.researchandmarkets.com/research/xq558m/global_cancer) has announced the addition of the "Global Cancer Vaccine Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering.
The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report provides details of the latest cancer vaccine agreements announced in the healthcare sectors covering the following diagnostics types including adjuvant.
- Attenuated vaccine
- Subunit vaccine
- Toxoid vaccine
- Conjugate vaccine
- Inactivated vaccine
- DNA vaccine
- Recombinant vector vaccine
Global Cancer Vaccine Partnering 2010-2015 includes:
- Trends in cancer vaccine dealmaking in the biopharma industry since 2010.
- Analysis of cancer vaccine deal structure.
- Access to headline, upfront, milestone and royalty data.
- Access to over 150 cancer vaccine deal records.
- The leading cancer vaccine deals by value since 2010.
In Global Cancer Vaccine Partnering 2010-2015 , the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific oncology therapy target
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Trends in cancer vaccine dealmaking
Chapter 3 Average financial deal terms for cancer vaccine partnering
Chapter 4 Leading cancer vaccine deals
Chapter 5 Cancer vaccine dealmaking contracts directory
Chapter 6 Cancer vaccine dealmaking by specific therapy type
Chapter 7 Cancer vaccine dealmaking by specific technology type
Chapter 8 Future trends and companies in cancer vaccine deal making
Chapter 9 Partnering resource center
For more information visit http://www.researchandmarkets.com/research/xq558m/global_cancer
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets